
AMAG
Healthcare · Biotechnology · $477.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2020
EPS trend, 90 days to now · -100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2020 | Time not confirmed | -0.01 | 1.19 | +12000.0% |
| Aug 6, 2020 | Time not confirmed | -0.19 | -0.23 | -21.1% |
| May 11, 2020 | Time not confirmed | -0.03 | -0.30 | -900.0% |
| Mar 4, 2020 | Time not confirmed | -0.35 | -0.35 | 0.0% |
| Nov 1, 2019 | Time not confirmed | -0.66 | -0.42 | +36.4% |
| Aug 7, 2019 | Time not confirmed | -0.57 | -0.87 | -52.6% |
| May 7, 2019 | Time not confirmed | -0.26 | -0.90 | -246.2% |
| Feb 7, 2019 | Time not confirmed | -0.88 | -0.60 | +31.8% |
| Nov 1, 2018 | Time not confirmed | -0.79 | -1.88 | -138.0% |
| Aug 2, 2018 | Time not confirmed | 0.26 | -0.75 | -388.5% |
| May 3, 2018 | Time not confirmed | -0.04 | -1.59 | -3875.0% |
| Feb 27, 2018 | Time not confirmed | 0.09 | 0.10 | +11.1% |
AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to…